Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

Chong EA, Levine BL, Grupp SA, Davis MM, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, Hwang WT, Chong ER, June CH, Schuster SJ.

Blood. 2019 Sep 25. pii: blood.2019002258. doi: 10.1182/blood.2019002258. [Epub ahead of print] No abstract available.

PMID:
31554634
2.

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL.

Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30.

PMID:
31420241
3.

Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines.

Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ, Beatty GL.

Cell Mol Gastroenterol Hepatol. 2019 Aug 6. pii: S2352-345X(19)30096-7. doi: 10.1016/j.jcmgh.2019.07.008. [Epub ahead of print] No abstract available.

4.

Hepatocytes direct the formation of a pro-metastatic niche in the liver.

Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O'Hara MH, Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL.

Nature. 2019 Mar;567(7747):249-252. doi: 10.1038/s41586-019-1004-y. Epub 2019 Mar 6.

5.

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.

Salas-Mckee J, Kong W, Gladney WL, Jadlowsky JK, Plesa G, Davis MM, Fraietta JA.

Hum Vaccin Immunother. 2019;15(5):1126-1132. doi: 10.1080/21645515.2019.1571893. Epub 2019 Apr 2.

PMID:
30735463
6.

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.

Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20.

7.

Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma.

Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL.

Clin Cancer Res. 2017 Jan 1;23(1):137-148. doi: 10.1158/1078-0432.CCR-16-0870. Epub 2016 Jun 28.

8.

IFN╬│ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.

Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL.

Cancer Discov. 2016 Apr;6(4):400-413. doi: 10.1158/2159-8290.CD-15-1032. Epub 2016 Feb 19.

9.

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.

Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH.

Gastroenterology. 2015 Jul;149(1):201-10. doi: 10.1053/j.gastro.2015.04.010. Epub 2015 Apr 14.

10.

Immune escape mechanisms as a guide for cancer immunotherapy.

Beatty GL, Gladney WL.

Clin Cancer Res. 2015 Feb 15;21(4):687-92. doi: 10.1158/1078-0432.CCR-14-1860. Epub 2014 Dec 12. Review.

Supplemental Content

Loading ...
Support Center